Abstract 200P
Background
TITAN demonstrated that APA + ADT improves radiographic progression-free survival and overall survival over placebo (PBO) + ADT in patients (pts) with mCSPC, including those with low- and high-volume disease, previous docetaxel use, and prior treatment for localized disease (Chi KN N Engl J Med 2019). The likelihood of meaningful deterioration in pt-reported pain and fatigue in TITAN is explored.
Methods
mCSPC pts were randomized 1:1 to receive either APA (240 mg daily; n = 525) or PBO (n = 527), in addition to continuous ADT; each treatment cycle (C) was 28 days. Pain and fatigue were assessed using the Brief Pain Inventory-Short Form (BPI-SF) and Brief Fatigue Inventory (BFI), at baseline and averaged over 7 consecutive days (D) (D -6 through D1 of each C). General estimating equations for logistic regression were used to estimate treatment-related differences in likelihood of worsening in pain or fatigue scores (worsening of ≥ 2 points in items from BPI-SF and BFI).Table:
200P
Pain | Fatigue | |||
---|---|---|---|---|
BPI-SF | BFI | |||
Item | OR* | p† | OR* | p† |
Worst pain or fatigue, past 24 hr | 0.84 | 0.087 | 1.05 | 0.693 |
Least pain, past 24 hr | 0.78 | 0.062 | NA | NA |
Pain on average | 0.82 | 0.057 | NA | NA |
Pain or fatigue right now | 0.84 | 0.169 | 0.98 | 0.863 |
Average pain score | 0.80 | 0.068 | NA | NA |
Pain or fatigue interference: | ||||
General activity | 0.83 | 0.151 | 1.02 | 0.849 |
Mood | 0.73 | 0.015 | 0.87 | 0.311 |
Walking | 0.82 | 0.129 | 0.93 | 0.549 |
Normal work | 0.86 | 0.232 | 1.00 | 0.976 |
Relations | 0.78 | 0.056 | 0.87 | 0.296 |
Sleep | 0.77 | 0.044 | NA | NA |
Enjoyment of life | 0.81 | 0.106 | 0.92 | 0.528 |
Overall interference score of pain or fatigue | 0.79 | 0.032 | 0.95 | 0.640 |
Usual fatigue, past 24 hr | NA | NA | 0.99 | 0.9044 |
hr, hours; NA, not on assessment; OR, adjusted odds ratio.
*Data from all time points, including baseline patient-reported outcome score and stratification factors.
†Nominal p-value, no adjustments of multiplicity.
Results
Median scores for pain (APA, 1.14; PBO, 1.00) and fatigue (APA, 1.29; PBO 1.43) on 0-10 severity scales indicated all pts were relatively asymptomatic at baseline. Pts treated with APA vs PBO consistently scored favorably in all BPI-SF pain severity– and pain interference–related questions, and had significantly lower risk of worsening pain interference with mood (p = 0.015), sleep (p = 0.044), and overall pain interference (p = 0.032; Table). Reduced risk of overall pain interference was observed by C18. In general, pt experience with fatigue was similar with APA and PBO (Table).
Conclusions
In a broad population of pts with mCSPC in TITAN, no additional pt-reported fatigue was observed with the addition of APA or PBO to ADT. Pts reported consistently favorable pain scores and less interference from pain in their daily lives with APA.
Clinical trial identification
NCT02489318.
Editorial acknowledgement
Editorial assistance was provided by Patricia McChesney, PhD, CMPP, of Parexel (Hackensack, NJ), and was funded by Janssen Research & Development.
Legal entity responsible for the study
Janssen Research & Development.
Funding
Janssen Research & Development.
Disclosure
B.H. Chung: Research grant / Funding (self), Travel / Accommodation / Expenses: Janssen (USA & Korea); Research grant / Funding (self): Bayer (Germany); Research grant / Funding (self): Pfizer (USA); Research grant / Funding (self): AstraZeneca (UK); Research grant / Funding (self): Roche (Switzerland); Research grant / Funding (self): Myovant Sciences GmbH (Australia); Travel / Accommodation / Expenses: Astellas (Korea); Travel / Accommodation / Expenses: Ipsen (Korea); Travel / Accommodation / Expenses: JW Pharma (Korea); Travel / Accommodation / Expenses: Takeda (Korea); Travel / Accommodation / Expenses: Handok (Korea); Travel / Accommodation / Expenses: Amgen (Korea). K. McQuarrie: Full / Part-time employment: Janssen Research & Development; Shareholder / Stockholder / Stock options: Johnson & Johnson. A. Bjartell: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses, Non-remunerated activity/ies: Janssen; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses, Non-remunerated activity/ies: Astellas; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses, Non-remunerated activity/ies: Bayer; Advisory / Consultancy, Travel / Accommodation / Expenses, Non-remunerated activity/ies: Incyte; Honoraria (self), Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: Ferring; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: IPSEN; Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options, Officer / Board of Directors: LIDDS Pharma; Research grant / Funding (self), Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options, Officer / Board of Directors, Non-remunerated activity/ies: Glactone Pharma/Development ; Shareholder / Stockholder / Stock options: WntResearch. S. Chowdhury: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Johnson & Johnson; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Astellas; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Sanofi; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: Clovis. Á. Juárez Soto: Advisory / Consultancy, Speaker Bureau / Expert testimony, Non-remunerated activity/ies, Publication Steering Committee TITAN & IP Clinical Trial SPARTAN: Janssen. A.S. Merseburger: Travel / Accommodation / Expenses, Non-remunerated activity/ies, support for clinical trial conduct: Janssen Cilag; Travel / Accommodation / Expenses, Non-remunerated activity/ies, support for clinical trial conduct: Astellas Pharma; Travel / Accommodation / Expenses, Non-remunerated activity/ies, support for clinical trial conduct: Roche. H. Uemura: Speaker Bureau / Expert testimony, Research grant / Funding (self): Janssen; Research grant / Funding (self): AstraZeneca; Research grant / Funding (self): Takeda; Research grant / Funding (self): Astellas; Speaker Bureau / Expert testimony, Research grant / Funding (self): Ono/BMS; Research grant / Funding (self): Taiho; Speaker Bureau / Expert testimony: Pfizer; Speaker Bureau / Expert testimony: Bayer; Speaker Bureau / Expert testimony: MSD; Speaker Bureau / Expert testimony: Novartis. R. Given: Speaker Bureau / Expert testimony: Janssen. B. Miladinovic: Full / Part-time employment: Janssen Research & Development; Shareholder / Stockholder / Stock options: Johnson & Johnson. N. Li: Full / Part-time employment: Janssen Research & Development; Shareholder / Stockholder / Stock options: Johnson & Johnson. S. Hudgens: Full / Part-time employment: Clinical Outcomes Solutions; Travel / Accommodation / Expenses: Janssen Research & Development. L. Floden: Full / Part-time employment: Clinical Outcomes Solutions; Travel / Accommodation / Expenses: Janssen Research & Development. A. Lopez-Gitlitz: Full / Part-time employment: Janssen Research & Development; Shareholder / Stockholder / Stock options: Johnson & Johnson. K.N. Chi: Research grant / Funding (self), Research grant / Funding (institution), Travel / Accommodation / Expenses, Institutional: Janssen; Research grant / Funding (self), Research grant / Funding (institution), Travel / Accommodation / Expenses, Institutional: Astellas; Research grant / Funding (institution), Travel / Accommodation / Expenses, Institutional: Essa ; Research grant / Funding (self), Research grant / Funding (institution), Travel / Accommodation / Expenses, Institutional: Sanofi; Travel / Accommodation / Expenses, Institutional: Bayer; Research grant / Funding (institution), Travel / Accommodation / Expenses, Institutional: Roche; Research grant / Funding (institution), Travel / Accommodation / Expenses, Institutional: AstraZeneca. N. Agarwal: Advisory / Consultancy: Astellas; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Argos; Advisory / Consultancy: Bristol Myers Squibb; Advisory / Consultancy: Bayer; Advisory / Consultancy: Clovis; Advisory / Consultancy: Eisai; Advisory / Consultancy: Exelixis; Advisory / Consultancy: EMD Serono; Advisory / Consultancy: Ely Lilly; Advisory / Consultancy: Foundation One; Advisory / Consultancy: Genentech; Advisory / Consultancy, Travel / Accommodation / Expenses: Janssen; Advisory / Consultancy: Merck; Advisory / Consultancy: Medivation; Advisory / Consultancy: Novartis; Advisory / Consultancy: Nektar; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Pharmacyclics. All other authors have declared no conflicts of interest.
Resources from the same session
74TiP - Phase I study of BI 836880, a VEGF/Ang2-blocking nanobody®, as monotherapy and in combination with BI 754091, an anti-PD-1 antibody, in Japanese patients (pts) with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
75P - A parallel deep learning network framework for whole-body bone scan image analysis
Presenter: Xiaorong Pu
Session: Poster display session
Resources:
Abstract
76P - Perception and satisfaction of cancer patients in clinical trials
Presenter: Jukyung Jeon
Session: Poster display session
Resources:
Abstract
77P - A prognostic nomogram for the prediction of neuroblastoma
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
80P - The clinical usefulness of a new fat-dissociation method to detect lymph nodes from surgically resected specimen in colorectal cancer: Prospective randomized study
Presenter: Shiki Fujino
Session: Poster display session
Resources:
Abstract
81P - Concurrent or consolidation chemotherapy during radiation as neoadjuvant treatment for locally advanced rectal cancer: A propensity score analysis from two prospective study
Presenter: JianWei Zhang
Session: Poster display session
Resources:
Abstract
82P - Body mass index, tumour location, and colorectal cancer survival
Presenter: Dake Chu
Session: Poster display session
Resources:
Abstract
83P - Helicobacter bilis may play a role in the carcinogenesis of colitis associated colon cancer correlating to increased number of CD4+CD45RB+ T cells
Presenter: Xiangsheng Fu
Session: Poster display session
Resources:
Abstract
84P - Comprehensive evaluation of relapse risk (CERR) score for colorectal liver metastases development and validation
Presenter: Jianmin Xu
Session: Poster display session
Resources:
Abstract
85P - Which is the best partner for capecitabine-based neoadjuvant chemoradiotherapy in locally advanced rectal cancer? A retrospective analysis of a comprehensive cancer center
Presenter: Jingwen Wang
Session: Poster display session
Resources:
Abstract